Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
about
Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyAssociations of sleep disturbance with ADHD: implications for treatmentNeuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopyNeuropharmacological effect of atomoxetine on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopyPatterns of psychotropic medication prescriptions by psychiatrists for private clinic outpatients in kerman province, iran.Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.Wake-promoting pharmacotherapy for psychiatric disorders.Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic reviewEffective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway.Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.Individual treatment response in attention-deficit/hyperactivity disorder: broadening perspectives and improving assessments.Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.Pozanicline for the treatment of attention-deficit/hyperactivity disorder.Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity.Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder.Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.Parenting teens with attention-deficit/hyperactivity disorder: challenges and opportunities.Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment.Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD.SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis.Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists.A clinician's guide to ADHD treatment options.Genetic Insights Into ADHD Biology.Predicting methylphenidate response in attention deficit hyperactivity disorder: A preliminary study
P2860
Q26750486-9C3E4B9D-3725-4A28-AEA0-16AF08B61A4CQ27027062-121AD290-91E3-4AEC-A8C8-7FBA4535353BQ28647972-575C474B-CEE9-498A-BB3F-A3BAF923248CQ28647973-26B807A7-152B-40DA-B868-65F7D06FE199Q33982992-D712B48A-0A20-4F92-A960-064DC2D89178Q34431858-B5C180E0-F56B-4D7F-8496-34F168C7D0A0Q34443394-9C0C5476-1EFA-483C-A823-476B4532A4AEQ36206061-9CE37961-5736-4C53-B97D-BF80FE53B5DCQ36298408-394B2553-F58A-43BD-8991-E688458F9CAFQ36925745-BDC16F02-D332-4D81-8847-D13CBB728A9EQ37115696-91C6577E-AF2D-4283-9F04-0C7464CD081DQ37196979-C6946AB2-20AF-42D1-BFB6-933539D148E6Q37330660-FF6E0E7B-463E-4FE0-ADD2-6BBABF0405A9Q37712616-8E99D218-B3F8-4368-BA4B-0F739FAF8563Q38094813-97AB0F41-E41B-47C9-8502-5DF19FF9BFA8Q38176839-49F9040A-28F0-4696-8F20-D7F3230ED089Q38239633-429044C0-EECC-4EEC-A93B-F15608F5BBF6Q38246678-AE56FAFB-6EBC-4D9E-9124-F2077492D47CQ38663434-2D9F7AC5-B131-4F0B-B1BA-F46823E0AE84Q38712796-61CC7C33-97DA-49B8-B838-F6CE6A1E1C09Q38836941-2BC95A13-32A0-4474-8ECF-7CCC1B61B789Q39266445-AB65501C-ABAB-413F-9ADB-80B4C6188DEFQ39735203-35D8DCE0-D18A-49B7-8A46-D29D2283B73EQ40058190-33A2BBEA-3E21-43F5-A6D9-EF4E5F6F46D7Q42113942-AA797397-3E6C-40DE-9A9E-861F4964EF83Q46121131-D8297CA3-E757-4B75-AB0D-F9F5323B0AB1Q47664709-C7DED396-DA59-4432-824C-5422535072BDQ47927866-B78BA334-2546-42B3-AFA1-80B14D866457Q48241287-F18D0063-C995-4DD1-855C-7117C28AF3AEQ49187017-B6CE8B8C-621F-4C81-8050-7971111ED6F9Q53132267-278A0818-2381-439F-BD9C-D7EEF6543F7DQ55266107-7C56A211-931D-46B8-AC07-15ECE15DF0FCQ57435671-EFD42BAA-184D-4B05-BA16-7CCE9C76EDF4
P2860
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Amfetamine and methylphenidate ...... omplementary treatment options
@ast
Amfetamine and methylphenidate ...... omplementary treatment options
@en
Amfetamine and methylphenidate ...... omplementary treatment options
@nl
type
label
Amfetamine and methylphenidate ...... omplementary treatment options
@ast
Amfetamine and methylphenidate ...... omplementary treatment options
@en
Amfetamine and methylphenidate ...... omplementary treatment options
@nl
prefLabel
Amfetamine and methylphenidate ...... omplementary treatment options
@ast
Amfetamine and methylphenidate ...... omplementary treatment options
@en
Amfetamine and methylphenidate ...... omplementary treatment options
@nl
P2093
P2860
P921
P1476
Amfetamine and methylphenidate ...... omplementary treatment options
@en
P2093
David Coghill
Lily Hechtman
Monica Shaw
Paul Hodgkins
P2860
P2888
P304
P356
10.1007/S00787-012-0286-5
P577
2012-07-05T00:00:00Z
2012-09-01T00:00:00Z